|
Extraskeletal Ewing Sarcoma of the Jejunum: A Case ReportColby Cantu, MD1; Elizabeth Bressler, MD1; Josephine Dermawan, MD, PhD2; Kristen Paral, MD1 Perm J 2019;23:18-255 [Full Citation] https://doi.org/10.7812/TPP/18-255E-pub: 06/07/2019ABSTRACTIntroduction: Ewing sarcoma most commonly arises in bones but rarely presents in extraskeletal locations. We report one such case arising from the jejunum. INTRODUCTIONEwing sarcoma most commonly affects the bony skeleton of patients younger than 20 years of age and is the second-most common pediatric sarcoma of the bone. Extraskeletal cases are rare, and these patients generally present at an older age and demonstrate a greater overall 5-year survival than skeletal Ewing sarcoma tumors.1,2 The most common sites of extraskeletal presentation are the chest wall, paravertebral region, lower extremities, and gluteal region.3,4 Reports of primary liver involvement have been noted, as well as gastrointestinal sites of origin, including the stomach, small intestine, and colorectum.5-8 Extraskeletal Ewing sarcoma of the small intestine is extremely rare, with only 16 reports found in the literature.9-24 Exhaustive unsuccessful attempts were made to contact this patient. An effort has been made to anonymize patient information so as to not cause harm to the patient. CASE PRESENTATIONPresenting ConcernsA 67-year-old woman presented with a 1-day history of acute-onset, right lower quadrant pain that radiated to the back. She reported never experiencing pain like this before. She reported recent constipation, but denied having nausea, emesis, fevers, night sweats, unintentional weight loss, and blood in the stool. She reported no personal or family history of malignancy. Results of spiral computed tomography scans of the abdomen and pelvis with intravenous contrast enhancement demonstrated a heterogeneous mass in the midjejunum with multiple foci of extraluminal free air adjacent to the mass. She was taken to the operating room for an exploratory laparotomy, which revealed a solitary midjejunum mass perforating through the small intestinal wall. The mass was excised. Pathologic FindingsGross findings showed a 5.7 x 4.5 x 4.4-cm, pink-tan, soft, and polypoid tumor. Formalin-fixed, paraffin-embedded sections of tumor stained with hematoxylin-eosin demonstrated sheets of densely packed primitive blue cells separated by broad fibrous septae, with areas of necrosis and focal rosette-like formations. The tumor transmurally involved the small bowel with mucosal ulceration. The individual tumor cells showed oval-to-angulated nuclei with frequent nuclear grooves, indistinct nucleoli, and minimal, clear cytoplasm (Figures 1 and 2). Scattered mitotic figures were also noted. On immunohistochemical analysis, the tumor was positive for vimentin, CD99 (Figure 3), CD117, and cyclin D1. The tumor was focally positive for S100 (Figure 4) but negative for SOX10. It was also negative for pancytokeratin, CAM5.2, synaptophysin, CD56, CD45, SF-1, FOXL2, DOG1, STAT6, CD10, CD21, CD35, CD43, TdT, CD163, MDM2, ER, calretinin, inhibin, muramidase, pan-melanoma, smooth muscle actin, desmin, and CD34. At this juncture, the histopathologic findings were consistent with Ewing sarcoma. However, malignant gastrointestinal neuroectodermal tumor (GNET) was also still a consideration in view of the S100 expression. Therefore, molecular studies were pursued to resolve this differential. Fluorescence in situ hybridization for an EWSR1 gene rearrangement (22q11) was performed using a dual-color, break-apart probe and revealed a positive result in 186 of 200 (93%) interphase nuclei (Figure 5). Therapeutic Intervention and TreatmentThe final pathologic diagnosis for the jejunal mass was extraskeletal Ewing sarcoma with associated EWSR1-FLI1 fusion. All operative margins and evaluated lymph nodes were negative for disease. The patient’s postoperative course was complicated by slow wound healing and wound infection. The poor performance status excluded multiagent adjuvant chemotherapy, so she was instead prescribed serial imaging surveillance. Follow-up and OutcomesHowever, the patient ultimately did not return for follow-up. Her outcome is unknown. Table 1 shows a timeline of the case. DISCUSSIONEwing sarcoma is known to harbor multiple balanced translocations, and fusions involving the EWSR1 gene on chromosome 22 exist. The most common translocation is t(11;22), EWSR1-FLI1 fusion (85% of cases), causing overexpression of the FLI-1 protein. The second most common translocation is t(21;22), EWSR1-ERG fusion (5%-10% of cases). Numerous other, less common variant translocations exist. Lack of reverse transcription-polymerase chain reaction fusion transcripts for EWSR1-FLI1 and EWSR1-ERG does not exclude the possibility of Ewing sarcoma because it does not rule out fusion transcripts that may be present below the limit of detection for the given assay (5%).25 For differentiation of small-intestine Ewing sarcoma from other diagnostic entities such as malignant GNET, malignant gastrointestinal stromal tumor, clear cell sarcoma, synovial sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor, and lymphoma, an exhaustive panel of immunohistochemical stains and fluorescence in situ hybridization tests are recommended. Malignant GNET is an extremely rare and recently recognized entity that was first described in 2003 and demonstrates overlapping features with Ewing sarcoma.26,27 It is histologically characterized by a sheet-like or nested population of primitive-appearing epithelioid or oval-to-spindle cells with small nucleoli and occasional mitoses. Occasionally, cytoplasmic clearing and osteoclast-type multinucleated giant cells may be evident. There is strong expression for neural markers (S100, SOX10, and vimentin) without expression for melanocytic markers. Rare reports of FLI1 expression have been reported.28 Similar to Ewing sarcoma, GNET shows EWSR1 gene rearrangements. The EWSR1 fusion partners in GNET are most commonly ATF1 or CREB1. These findings raise the issue of whether Ewing sarcoma may be related to GNET. CONCLUSIONWe have described a patient with Ewing sarcoma occurring in the small intestine. This case report helps solidify the small intestine as a potential site for Ewing sarcoma origin, and helps highlight the need for robust immunohistochemical and molecular cytogenetic analysis for accurate diagnosis. Disclosure StatementThe author(s) have no conflicts of interest to disclose. AcknowledgmentsKathleen Louden, ELS, of Louden Health Communications performed a primary copy edit. How to Cite this ArticleCantu C, Bressler E, Dermawan J, Paral K. Extraskeletal Ewing sarcoma of the jejunum: A case report. Perm J 2019;23:18-255. DOI: https://doi.org/10.7812/TPP/18-255 Author Affiliations1 Department of Pathology, Duke University Health System, Durham, NC 2 Department of Pathology, Cleveland Clinic, OH Corresponding AuthorColby Cantu, MD () References1. Pradhan A, Grimer RJ, Spooner D, et al. Oncological outcomes of patients with Ewing’s sarcoma: Is there a difference between skeletal and extra-skeletal Ewing’s sarcoma? J Bone Joint Surg Br 2011 Apr;93(4):531-6. DOI: https://doi.org/10.1302/0301-620X.93B4.25510.
|
ETOC
Click here to join the eTOC list or text ETOC to 22828. You will receive an email notice with the Table of Contents of The Permanente Journal.
CIRCULATION
2 million page views of TPJ articles in PubMed from a broad international readership.
Indexing
Indexed in MEDLINE, PubMed Central, EMBASE, EBSCO Academic Search Complete, CrossRef, and SciVerse/Scopus.